With millions of COVID-19 cases reported across the globe, people are turning to antibody tests to find out whether they have been exposed to the coronavirus that causes the disease. But what are antibodies? Why are they important? If we have them, are we immune to COVID-19? And if not, why not?
Antibody tests look for the presence of antibodies, which are specific proteins made in response to infections. Antibodies are disease specific. For example, measles antibodies will protect you from getting measles if you are exposed to it again, but they won't protect you from getting mumps if you are exposed to mumps.
"Antibodies are important because they prevent infection and heal patients affected by diseases," said Victor Padilla-Sanchez, a researcher at The Catholic University of America in Washington D.C. "If we have antibodies, we are immune to disease, as long as they are in your system, you are protected. If you don't have antibodies, then infection proceeds and the pandemic continues."
This form of foreign-antibody-based protection is called passive immunity—short-term immunity provided when a person is given antibodies to a disease rather than producing these antibodies through their own immune system.
"We're at the initial steps of this now, and this is where I'm hoping my work might help," Padilla-Sanchez said. Padilla-Sanchez specializes in viruses. Specifically, he uses computer models to understand the structure of viruses on the molecular level and uses this information to try to figure out how the virus functions.
Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the 21st century. This respiratory illness originated in the Guangdong province of China in November 2002. The World Health Organization identified this new coronavirus (SARS-CoV) as the agent that caused the outbreak.
Now we're in the middle of yet another new coronavirus (SARS-CoV-2), which emerged in Wuhan, China in 2019. COVID-19, the disease caused by SARS-CoV-2, has become a rapidly spreading pandemic that has reached most countries in the world. As of July 2020, COVID-19 has infected more than 15.5 million people worldwide with more than 630,000 deaths.
Structural analysis of SARS-CoV spike glycoprotein. In A the SARS-CoV spike protein (PDB ID: 6ACG) is shown bound to ACE2 (brown) and 80R antibody (cyan), superimposed on the same binding site. In B the spike protein is shown bound only to the 80R antibody (PDB ID: 2GHW), with the structural model of the RBD of the SARS-CoV-2 spike protein (magenta) containing the missing loops. This homology model served as the basis for the docking experiments. In C it is shown a spike colored by subunit and showing the glycans. There are only two possible glycans in RBD region at 331 and 343 and neither of these sites affect the 80R binding. Credit: Victor Padilla-Sanchez, Researcher, The Catholic University of America
To date, there are not any vaccines or therapeutics to fight the illness.
Since both illnesses (SARS-CoV and SARS-CoV-2) share the same spike protein, the entry key that allows the virus into the human cells, Padilla-Sanchez's idea was to take the antibodies found in the first outbreak in 2002—80R and m396—and reengineer them to fit the current COVID-19 virus.
A June 2020 study in the online journal, Research Ideas and Outcomes, describes efforts by Padilla-Sanchez to unravel this problem using computer simulation. He discovered that sequence differences prevent 80R and m396 from binding to COVID-19.
"Understanding why 80R and m396 did not bind to the SARS-CoV-2 spike protein could pave the way to engineering new antibodies that are effective," Padilla-Sanchez said. "Mutated versions of the 80r and m396 antibodies can be produced and administered as a therapeutic to fight the disease and prevent infection."
His docking experiments showed that amino acid substitutions in 80R and m396 should increase binding interactions between the antibodies and SARS-CoV-2, providing new antibodies to neutralize the virus.
"Now, I need to prove it in the lab," he said.
For his research, Padilla-Sanchez relied on supercomputing resources allocated through the Extreme Science and Engineering Discovery Environment (XSEDE). XSEDE is a single virtual system funded by the National Science Foundation used by scientists to interactively share computing resources, data, and expertise.
Docking interface between the modified 80R antibody and the RBD of the SARS-CoV-2 spike protein. The model shows the structural interface with the 80R antibody above and the RBD below. The seven substitutions in 80R are shown in magenta and RBD residues are shown in cyan. Notice how the substitutions in 80R allow new aromatic-aromatic interactions that improve binding to the RBD and are not present in wild type 80R. E484 is shown pointing towards the beta strand of 80R and a glycine substitution was therefore introduced to avoid clashes. Credit: Victor Padilla-Sanchez, Researcher, The Catholic University of America
The XSEDE-allocated Stampede2 and Bridges systems at the Texas Advanced Computing Center (TACC) and Pittsburgh Supercomputer Center supported the docking experiments, macromolecular assemblies, and large-scale analysis and visualization.
"XSEDE resources were essential to this research," Padilla-Sanchez said.
He ran the docking experiments on Stampede2 using the Rosetta software suite, which includes algorithms for computational modeling and analysis of protein structures. The software virtually binds the proteins then provides a score for each binding experiment. "If you find a good docking position, then you can recommend that this new, mutated antibody should go to production."
TACC's Frontera supercomputer, the 8th most powerful supercomputer in the world and the fastest supercomputer on a university campus, also provided vital help to Padilla-Sanchez. He used the Chimera software on Frontera to generate extremely high-resolution visualizations. From there, he transferred the work to Bridges because of its large memory nodes.
"Frontera has great performance when importing a lot of big data. We're usually able to look at just protein interactions, but with Frontera and Bridges, we were able to study full infection processes in the computer," he said.Padilla-Sanchez's findings will be tested in a wet lab. Upon successful completion of that stage, his work can proceed to human trials.
Currently, various labs across the world are already testing vaccines.
"If we don't find a vaccine in the near term we still have passive immunity, which can prevent infection for several months as long as you have the antibodies," Padilla-Sanchez said. "Of course, a vaccine is the best outcome. However, passive immunity may be a fast track in providing relief for the pandemic."
More information: Victor Padilla-Sanchez, In silico analysis of SARS-CoV-2 spike glycoprotein and insights into antibody binding, Research Ideas and Outcomes (2020). DOI: 10.3897/rio.6.e55281